Is a Form 483 the same as a Warning Letter?

No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.

Where can I read the full Form 483?

The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.

What is an FDA Form 483?

A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.

The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories — FDA Form 483 Inspection, March 20, 2026 (1 Citations)

Here's the summary: FDA inspected The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories in Tennessee, USA and issued a Form 483 listing 1 inspectional observation following an inspection that concluded 2026-03-20. FDA's inspection record does not classify The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories's facility type further. A Form 483 documents an investigator's findings at the close of an inspection under the Federal Food, Drug, and Cosmetic Act; it is not a final agency compliance determination. The observations on this page are drawn directly from the FDA-issued Form 483 record.

Key facts

Firm	The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories
FEI / inspection ID	1818658
Inspection end date	March 20, 2026
Citation count	1

Citations explained

Observation 1 — -- 1 of 4 -- -- 2 of 4 -- -- 3 of 4 -- -- 4 of 4

-- 1 of 4 -- -- 2 of 4 -- -- 3 of 4 -- -- 4 of 4 -- A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it. A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

What a Form 483 means

A Form FDA 483 is issued at the close of an FDA facility inspection to list conditions an investigator observed that may violate the Federal Food, Drug, and Cosmetic Act or its implementing regulations. It reflects the investigator's professional judgment at that point in time and is not a final agency determination, an enforcement action, or proof that a violation occurred. Firms are expected to respond in writing, typically within 15 business days, describing the corrective and preventive actions they plan to take. FDA reviews that response, along with any follow-up evidence, before deciding what happens next. Many 483s are resolved through corrective action alone. When FDA judges a firm's response inadequate, or when the underlying conditions are serious enough, the observations documented here can lead to a Warning Letter or further regulatory action. This page presents the observations exactly as recorded on the FDA-issued document; always confirm citation language against the original record before relying on it.

The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories’s FDA history

Argus HQ has recorded 1 total FDA action tied to The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories: 0 warning letters, 0 recalls, 0 approval records, and 1 Form 483 inspection citation.

Frequently asked questions

Is a Form 483 the same as a Warning Letter?: No. A Form 483 lists an FDA investigator’s observations at the close of an inspection; it is not a final agency determination. FDA may or may not follow up with a Warning Letter depending on the firm’s response and the severity of the findings.
Where can I read the full Form 483?: The verbatim inspection record is the source of truth — always confirm citation language against the original FDA document before acting.
What is an FDA Form 483?: A Form FDA 483 lists an FDA investigator’s written observations at the close of a facility inspection, issued under section 704(b) of the Federal Food, Drug, and Cosmetic Act. It documents conditions the investigator judged may violate FDA regulations. A 483 is not an enforcement action or a final determination that a violation occurred.
Does this Form 483 mean The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories violated the law?: No. A Form 483 documents an investigator's observations only. FDA reviews the firm's written response and any corrective actions taken before deciding whether further action is warranted, and many 483s are closed without additional enforcement once a firm shows adequate correction.

See if this 483 escalates to a warning letter — before your auditor asks.

Free weekly briefing tracks every FDA inspection outcome.

Full FDA history for The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories — FDA Form 483 Inspection, March 20, 2026 (1 Citations). Digital Empire Holdings LLC. Retrieved from https://argushq.ai/483/the-harvard-drug-group-dba-major-pharmaceutical-and-rugby-laboratories-1818658-2026-03-20

MLA

"The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories — FDA Form 483 Inspection, March 20, 2026 (1 Citations)." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/483/the-harvard-drug-group-dba-major-pharmaceutical-and-rugby-laboratories-1818658-2026-03-20.

Chicago

Argus HQ Research. "The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories — FDA Form 483 Inspection, March 20, 2026 (1 Citations)." Digital Empire Holdings LLC. Accessed August 17, 2026. https://argushq.ai/483/the-harvard-drug-group-dba-major-pharmaceutical-and-rugby-laboratories-1818658-2026-03-20.

BibTeX

@misc{argushq_argushq_ai_483_the_harvard_drug_group_dba_major_pharmaceutical_and_rugby_laboratories_1818658_2026_03_20_2026,
  title = {The Harvard Drug Group, LLC dba Major Pharmaceutical and Rugby Laboratories — FDA Form 483 Inspection, March 20, 2026 (1 Citations)},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/483/the-harvard-drug-group-dba-major-pharmaceutical-and-rugby-laboratories-1818658-2026-03-20},
  note = {Accessed: August 17, 2026}
}

Source: FDA.gov — Inspection Classification Database ↗